CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-01 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2024-02-01 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Grant or award · Stock Option (Right to Buy) | +304,500 | 304,500 | ||
| 2024-02-01 | Bohen Sean PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +621,500 | 621,500 | ||
| 2024-02-01 | Harmon Cyrus Director | Sale 10b5-1 | −5,000 | $15.56 | $78K | 871,283 |
| 2024-01-31 | Harmon Cyrus Director | Sale 10b5-1 | −25,000 | $12.23 | $306K | 876,283 |
| 2024-01-25 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise | +20,000 | $7.02 | $140K | 66,664 |
| 2024-01-25 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) | −20,000 | 214,000 | ||
| 2024-01-12 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Option exercise | +50,000 | $7.02 | $351K | 484,987 |
| 2024-01-12 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Option exercise · Stock Option (Right to Buy) | −50,000 | 187,000 | ||
| 2023-12-29 | Harmon Cyrus Director | Sale | −22,500 | $13.30 | $299K | 903,783 |
| 2023-12-29 | Harmon Cyrus Director | Sale | −2,500 | $14.10 | $35K | 901,283 |
| 2023-12-12 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Option exercise | +10,000 | $7.02 | $70K | 434,987 |
| 2023-12-12 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Option exercise · Stock Option (Right to Buy) | −10,000 | 237,000 | ||
| 2023-12-11 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise | +2,900 | $7.02 | $20K | 46,664 |
| 2023-12-11 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) | −2,900 | 234,000 | ||
| 2023-12-06 | Paradigm Biocapital Advisors LP 10% owner | Purchase | +100,000 | $11.60 | $1.2M | 6,590,981 |
| 2023-12-06 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise | +13,100 | $7.02 | $92K | 43,764 |
| 2023-12-06 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) | −13,100 | 236,900 | ||
| 2023-12-05 | Graham G. Walmsley Director | Purchase | +31,870 | $14.73 | $470K | 1,700,000 |
| 2023-12-05 | Graham G. Walmsley Director | Purchase | +50,000 | $14.95 | $747K | 1,750,000 |
Page 10 of 11 · 207 trades